Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy-Reference-Cited by-同舟云学术

Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy

Published:2020-04-28 Issue:1 Volume:374 Page:211-222
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Shin Niu,Stubbs Matthew,Koblish Holly,Yue Eddy W.,Soloviev Maxim,Douty Brent,Wang Kathy He,Wang Qian,Gao Mingming,Feldman Patricia,Yang Gengjie,Hall Leslie,Hansbury Michael,O’Connor Sybil,Leffet Lynn,Collins Robert,Katiyar Kamna,He Xin,Waeltz Paul,Collier Paul,Lu Jin,Li Yun-Long,Li Yanlong,Liu Phillip C.C.,Burn Timothy,Covington Maryanne,Diamond Sharon,Shuey Dana,Roberts Alan,Yeleswaram Swamy,Hollis Greg,Metcalf Brian,Yao Wenqing,Huber Reid,Combs Andrew,Newton Robert,Scherle Peggy

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference46 articles.

1. Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition

2. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

3. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs

4. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study;Burris;Lancet Oncol,2018

5. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting;Chaudhary;Vaccines (Basel),2016

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From lab to clinic: The discovery and optimization journey of PI3K inhibitors;European Journal of Medicinal Chemistry;2024-11

2. A highly selective PI3Kδ inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon;Neoplasia;2024-11

3. Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions;Molecular Cancer;2024-08-10

4. TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas;Life Sciences;2024-06

5. Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma;Signal Transduction and Targeted Therapy;2024-04-17